Not us, says Apotex
July 17, 2012
APOTEX has joined a number of
other generic companies in denial
that it’s initiated the 25% price cut
for atorvastatin which is set to
become effective 01 Dec (PD yest).
Alphapharm and Ranbaxy have
also denied the move, along with
Ascent, Generic Health, Spirit,
Stada, Southern Cross Pharma and
Sandoz.
Pfizer hasn’t responded to an
enquiry from PD at this stage, but
appears to be the only sponsor not
to deny initiating the cut.
In a statement issued yesterday
Apotex said the 25% cut has
triggered an ad-hoc review of the
Statins Higher Potency group which
would make atorvastatin the
benchmark drug.
It will also see rosuvastatin have a
20.81% price reduction to equal
that of atorvastatin if no further
pricing proposals are made.
“Please note that Apotex has no
information to suggest that the
above price reductions are related
to the currently in process general
‘statin’ review that aims to review
the prices of all statins currently
listed on the PBS,” Alphapharm said.
The above article was sent to subscribers in Pharmacy Daily's issue from 17 Jul 12To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 17 Jul 12
